Rheumatology Drugs - FOI Response Register

1. We are analysing the usage of biologic and biosimilar products within Rheumatology and it would be really helpful if you could please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Where we have given <5 numbers, this is because NHS Shetland considers that providing  more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.